SEARCH

SEARCH BY CITATION

References

  • 1
    Tsui JKC, Eisen A, Stoessl AJ, et al. Double blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:2457.
  • 2
    Elston JS, Lee J. Clinical use of botulinum toxin. Lancet 1988;2:1139.
  • 3
    Quinn N, Hallett M. Dose standardisation of botulinum toxin. Lancet 1989;1:964.
  • 4
    Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:118694.
  • 5
    Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:8099.
  • 6
    Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:4934.
  • 7
    Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719.
  • 8
    Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994;344:4745.
  • 9
    Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003;31:26576.
  • 10
    Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:6977.
  • 11
    Rzany B, Zielke H. Overview of botulinum toxin. In: RzanyB, De MaioM, editors. Botulinum toxin in aesthetic medicine. Berlin: Springer; 2007. p. 19.
  • 12
    Bigalke H. Botulinumtoxine: Wirksamkeit und Antigenizität. Klin Neurophysiol 2001;32:2102.
  • 13
    Bigalke H, Irma A, Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol 2001;168:16270.
  • 14
    Wohlfarth K, Goschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355:33540.
  • 15
    Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19 (Suppl 8):12936.
  • 16
    Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005;21:4338.
  • 17
    Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005;20:93744.
  • 18
    Sackett DL, Straus S, Richardson WS, et al. Evidence-based medicine. Edinburgh: Churchill Livingstone; 2000.
  • 19
    Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:8409.
  • 20
    Sommer B, Bergfeld D, Sattler G. Consensus recommendations on the use of botulinum toxin type A in aesthetic medicine. J Dtsch Dermatol Ges 2007; (Suppl 1):129.
  • 21
    Karsai S, Adrian R, Hammes S, et al. A randomized double-blinded study of the effect of Dysport®/Reloxin® and Botox® on forehead wrinkles and EMG activity. Arch Dermatol 2007;143:14479.
  • 22
    Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006;55:97580.
  • 23
    Rzany B, Nast A. Head-to-head studies of botulinum toxin A in aesthetic medicine: which evidence is good enough? J Am Acad Dermatol 2007;56:10667.
  • 24
    Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007;33 (1 Spec No.):519.
  • 25
    Heckmann M, Schön-Hupka G. Quantification of the efficacy of botulinum toxin type A by digital image analysis. J Am Acad Dermatol 2001;45:50814.
  • 26
    Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004;51:22333.
  • 27
    Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005;31:41422.
  • 28
    Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005;31:1297303.
  • 29
    Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006;142:3206.
  • 30
    Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:108998.
  • 31
    Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:45962.
  • 32
    Poewe W. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:430.
  • 33
    Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:612.
  • 34
    Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®. J Neurol Neurosurg Psychiatry 1998;64:137.
  • 35
    Brisinda G, Albanese A, Cadeddu F, et al. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized ‘Botox vs. Dysport’ controlled trial. Aliment Pharmacol Ther 2004;19:695701.
  • 36
    Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1. Mov Disord 1997;12:10138.
  • 37
    Nüßgens Z, Roggenkämper P. Comparison of two botulinum neurotoxin preparations in the treatment of essential blepharospasm. Graefe's Arch Clin Exp Ophthalmol 1997;235:1979.
  • 38
    Simonetta-Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149:10415.
  • 39
    Trindade de Almeida AR, Marques E, De Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007;33 (1 Spec No.):3743.
  • 40
    Talarico-Filho S, Mendonca DO, Nascimento M, et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007;33 (1 Spec No.):4450.
  • 41
    Hexsel DM. Equipotent doses of botulinum toxin type A products share same radius of action. Dermatol Times 2005;9:66.
  • 42
    De Almeida A, Marques J, De Almeida J, et al. Pilot study comparing the diffusion characteristics of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. American Academy of Dermatology: 64th Annual Meeting; March 2006.
  • 43
    Wohlfarth K, Wegner F, Schwandt I, et al. Pharmacokinetic properties of different preparations of botulinum neurotoxin type A. Poster presented at the 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Denver, CO, June 23–25, 2005.
  • 44
    Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998;78:2315.
  • 45
    Rosales R, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neur 2006;13:210.
  • 46
    U.S. Food and Drug Administration. http://www.fda.gov/cder/biologics/products/botuall041202.htm (accessed January 2008).
  • 47
    Sloop RR, Escutin RO, Matus JA, et al. Dose response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996;46:13826.